| Name | Ozanimod hydrochloride |
| Description | Ozanimod hydrochloride (RPC-1063 hydrochloride) is an orally available, selective and potent sphingosine 1-phosphate (S1P) receptor modulator that shows high affinity for S1P1 and S1P5.Ozanimod has potential anticancer activity and can be used in the study of multiple sclerosis (MS), ulcerative multiple sclerosis (UMS), and other diseases. (MS), ulcerative colitis, coronavirus infections and myelodysplasia. |
| In vitro | Ozanimod hydrochloride, as a sphingosine-1-phosphate (S1P) receptor modulator, selectively binds with high affinity to S1P receptor subtypes 1 (S1P1) and S1P5[1]. |
| In vivo | In the experimental autoimmune encephalomyelitis (EAE) model, Ozanimod hydrochloride (0.05, 0.2, or 1 mg/kg; oral gavage; once daily; for 14 consecutive days) alleviated weight loss, with significantly reduced terminal disease scores observed in the 0.2 and 1 mg/kg dose groups. Moreover, cell counts were significantly reduced in all dose groups[1]. |
| Storage | keep away from direct sunlight,keep away from moisture,store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (11.34 mM), Sonication is recommended. DMSO : 150 mg/mL (340.2 mM), Sonication is recommended.
|
| Keywords | S1PReceptor | S1P Receptor | S1P |
| Inhibitors Related | LX-2931 | Tyloxapol | Sphingosine-1-phosphate | CYM50374 | ASP-4058 | CAY10444 | Ki16198 | Siponimod | CYM5181 | Poloxamer 407 | S1PR1 modulator 1 | MP-A08 |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |